Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Free Report) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totaling 48,068 shares, an increase of 96.3% from the May 31st total of 24,488 shares. Approximately 1.7% of the company’s shares are sold short. Based on an average trading volume of 29,463 shares, the days-to-cover ratio is currently 1.6 days.
Cyclerion Therapeutics Stock Up 0.7%
Cyclerion Therapeutics stock traded up $0.03 during trading hours on Wednesday, reaching $3.42. 4,630 shares of the company’s stock were exchanged, compared to its average volume of 3,067,121. The firm’s 50 day simple moving average is $3.14 and its 200 day simple moving average is $2.25. Cyclerion Therapeutics has a twelve month low of $1.03 and a twelve month high of $8.48. The firm has a market capitalization of $14.79 million, a PE ratio of -2.51 and a beta of 1.78.
Cyclerion Therapeutics (NASDAQ:CYCN – Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($17.20) by $16.44. Cyclerion Therapeutics had a negative return on equity of 62.10% and a negative net margin of 170.11%. Analysts anticipate that Cyclerion Therapeutics will post -1.2 EPS for the current year.
Analysts Set New Price Targets
Read Our Latest Analysis on Cyclerion Therapeutics
Institutional Inflows and Outflows
A hedge fund recently bought a new position in Cyclerion Therapeutics stock. Two Sigma Investments LP acquired a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned 0.40% of Cyclerion Therapeutics as of its most recent filing with the Securities & Exchange Commission. 75.62% of the stock is owned by institutional investors.
About Cyclerion Therapeutics
Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.
The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.
Read More
- Five stocks we like better than Cyclerion Therapeutics
- Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases
- Comcast’s NBCUniversal Split Puts Broadband Back in Focus
- 3 European Stocks to Carry Investors Through the Back Half of 2026
- Ouster Is Breaking Out as a Physical AI Leader: Here’s What’s Driving the Move
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
